Abstract:Introduction: Metastasis and drug resistance contribute substantially to the poor prognosis of colorectal cancer (CRC) patients. However, the epigenetic regulatory mechanisms by which CRC develops metastatic and drug-resistant characteristics remain unclear. This study aimed to investigate the role of miR-302a in the metastasis and molecular-targeted drug resistance of CRC and elucidate the underlying molecular mechanisms. Methods: miR-302a expression in CRC cell lines and patient tissue microarrays was analyzed by qPCR and fluorescence in situ hybridization. The roles of miR-302a in metastasis and cetuximab (CTX) resistance were evaluated both in vitro and in vivo. Bioinformatic prediction algorithms and luciferase reporter assays were performed to identify the miR-302a binding regions in the NFIB and CD44 3'-UTRs. A chromatin immunoprecipitation assay was performed to examine NFIB occupancy in the ITGA6 promoter region. Immunoblotting was performed to identify the EGFR-mediated pathways altered by miR-302a. Results: miR-302a expression was frequently reduced in CRC cells and tissues, especially in CTX-resistant cells and patient-derived xenografts. The decreased miR-302a levels correlated with poor overall CRC patient survival. miR-302a overexpression inhibited metastasis and restored CTX responsiveness in CRC cells, whereas miR-302a silencing exerted the opposite effects. NFIB and CD44 were identified as novel targets of miR-302a. miR-302a inhibited the metastasis-promoting effect of NFIB that physiologically activates ITGA6 transcription. miR-302a restored CTX responsiveness by suppressing CD44-induced cancer stem cell-like properties and EGFR-mediated MAPK and AKT signaling. These results are consistent with clinical observations indicating that miR-302a expression is inversely correlated with the expression of its targets in CRC specimens. Conclusions: Our findings show that miR-302a acts as a multifaceted regulator of CRC metastasis and CTX resistance by targeting NFIB and CD44, respectively. Our study implicates miR-302a as a candidate prognostic predictor and a therapeutic agent in CRC.

Mir-191 Promotes Tumorigenesis of Human Colorectal Cancer Through Targeting C/EBPβ.

Mir-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2

H19-Derived Mir-675 Functions As An Oncogenic Microrna In Human Colorectal Cancers Through Targeting The Rb Tumor Suppressor

Mir-4746 inhibits the proliferation of colorectal cancer cells in vitro and in vivo by targeting CCND1

Mir-942-5p Inhibits Proliferation, Metastasis, and Epithelial-Mesenchymal Transition in Colorectal Cancer by Targeting CCBE1

Mir-193B Directly Targets STMN1 and Inhibits the Malignant Phenotype in Colorectal Cancer.

Decreased Expression of Mir‑490‑3p in Colorectal Cancer Predicts Poor Prognosis and Promotes Cell Proliferation and Invasion by Targeting RAB14.

Correction: Mir-135B Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer.

Mir-320B Suppresses Cell Proliferation by Targeting C-Myc in Human Colorectal Cancer Cells.

Mir-150-5p Suppresses Tumor Progression by Targeting VEGFA in Colorectal Cancer

Mir-155 Regulates the Proliferation and Cell Cycle of Colorectal Carcinoma Cells by Targeting E2f2

Mir-592 Inhibited Cell Proliferation Of Human Colorectal Cancer Cells By Suppressing Of Ccnd3 Expression

Mir-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A.

Mir-203 A-3 P Promotes Colorectal Cancer Proliferation and Migration by Targeting PDE 4 D

Mir-938 Promotes Colorectal Cancer Cell Proliferation Via Targeting Tumor Suppressor Phlpp2

MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer

Mir-494 Is An Independent Prognostic Factor And Promotes Cell Migration And Invasion In Colorectal Cancer By Directly Targeting Pten

Mir-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells.

Mir-888 Functions As an Oncogene and Predicts Poor Prognosis in Colorectal Cancer.

Mir-302A Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44.

Mir-455-3p Functions As a Tumor Suppressor in Colorectal Cancer and Inhibits Cell Proliferation by Targeting TPT1.